Retrospective Study
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Mar 15, 2024; 16(3): 787-797
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.787
Figure 1
Figure 1 Immunohistochemical staining of patatin like phospholipase domain containing 8 protein in colorectal cancer specimens. Representative immunohistochemistry images show the staining intensities of patatin like phospholipase domain containing 8 protein, which were scored as 0 ("-"), 1 ("+"), 2 ("++"), and 3 ("+++"). Scale bar: 200 µm.
Figure 2
Figure 2 Kaplan-Meier analyses of overall survival rates in 751 colorectal cancer patients with a low or high patatin like phospholipase domain containing 8 protein expression. The colorectal cancer (CRC) patients with a high patatin like phospholipase domain containing 8 (PNPLA8) expression (n = 420) had an overall survival (OS) rate (P = 0.005) than those with a low PNPLA8 expression (n = 331) as determined using the Kaplan-Meier method.
Figure 3
Figure 3 Patatin like phospholipase domain containing 8 protein expression according to TNM stage and tumor location. A: Patients at stage I and stage II [n = 153 for patatin like phospholipase domain containing 8 (PNPLA8) low group; n = 200 for PNPLA8 high group]; B: Patients at stage III and stage IV (n = 178 for PNPLA8 low group; n = 220 for PNPLA8 high group); C: Patients with left-sided colon cancer (n = 92 for PNPLA8 low group; n = 108 for PNPLA8 high group); D: Patients with right-sided colon cancer (n = 97 for PNPLA8 low group; n = 112 for PNPLA8 high group); E: Patients with rectal cancer (n = 142 for PNPLA8 low group; n = 200 for PNPLA8 high group). The hazard ratio (HR), 95% confidence interval (95%CI), and log-rank P values are indicated in each panel. OS: Overall survival.